Jean-Paul Vincent

Jean-Paul Vincent

Auto-generated profile, based on publicly available information

Jean-Paul Vincent

The Francis Crick Institute, London, UK

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2015 in Nature
Verified
Journal Article
Open access
PDF file
SKSatoshi Kakugawa
Satoshi Kakugawa
PLPaul F. Langton
Paul F. Langton
MZMatthias Zebisch
Matthias Zebisch
SHSteven A. Howell
Steven A. Howell
TCTao-Hsin Chang
Tao-Hsin Chang
JVJean-Paul Vincent
Jean-Paul Vincent
Signalling by Wnt proteins is finely balanced to ensure normal development and tissue homeostasis while avoiding diseases such as cancer. This is achieved in part by Notum, a highly conserved secreted feedback antagonist. Notum has been thought to act as a phospholipase, shedding glypicans and associated Wnt proteins from the cell surface. However, this view fails to explain specificity, as glypicans bind many extracellular ligands. Here we provide genetic evidence in Drosophila that Notum requires glypicans to suppress Wnt signalling, but does not cleave their glycophosphatidylinositol anchor. Structural analyses reveal glycosaminoglycan binding sites on Notum, which probably help Notum to co-localize with Wnt proteins. They also identify, at the active site of human and Drosophila Notum, a large hydrophobic pocket that accommodates palmitoleate. Kinetic and mass spectrometric analyses of human proteins show that Notum is a carboxylesterase that removes an essential palmitoleate moiety from Wnt proteins and thus constitutes the first known extracellular protein deacylase.

25 December 2013 in Nature
Verified
Journal Article
Closed access
PDF file
CACyrille Alexandre
Cyrille Alexandre
ABAlberto Baena-Lopez
Alberto Baena-Lopez
JVJean-Paul Vincent
Jean-Paul Vincent

15 March 2009 in Nature Cell Biology
Verified
Journal Article
Closed access
CHCatherine Hogan
Catherine Hogan
SDSophie Dupré-Crochet
Sophie Dupré-Crochet
MNMark Norman
Mark Norman
MKMihoko Kajita
Mihoko Kajita
CZCarola Zimmermann
Carola Zimmermann
YFYasuyuki Fujita
Yasuyuki Fujita

1 October 2007 in Current Biology
Verified
Journal Article
Closed access
TRTor Erik Rusten
Tor Erik Rusten
thomas vaccarithomas vaccari
thomas vaccari
KLKarine Lindmo
Karine Lindmo
LRLina M.W. Rodahl
Lina M.W. Rodahl
INIoannis Nezis
Ioannis Nezis
HSHarald Stenmark
Harald Stenmark

1 October 1996 in Nature
Verified
Journal Article
Closed access
BÉBénédicte
Bénédicte
BSB Sanson
B Sanson
PWPhoebe White
Phoebe White
JVJean-Paul Vincent
Jean-Paul Vincent

1 December 2013 in Development
Verified
Journal Article
Open access
PDF file
LBLuis Alberto Baena-Lopez
Luis Alberto Baena-Lopez
CACyrille Alexandre
Cyrille Alexandre
AMAlice Mitchell
Alice Mitchell
LPLaurynas Pasakarnis
Laurynas Pasakarnis
JVJean-Paul Vincent
Jean-Paul Vincent
Gene targeting by ‘ends-out’ homologous recombination enables the deletion of genomic sequences and concurrent introduction of exogenous DNA with base-pair precision without sequence constraint. In Drosophila, this powerful technique has remained laborious and hence seldom implemented. We describe a targeting vector and protocols that achieve this at high frequency and with very few false positives in Drosophila, either with a two-generation crossing scheme or by direct injection in embryos. The frequency of injection-mediated gene targeting can be further increased with CRISPR-induced double-strand breaks within the region to be deleted, thus making homologous recombination almost as easy as conventional transgenesis. Our targeting vector replaces genomic sequences with a multifunctional fragment comprising an easy-to-select genetic marker, a fluorescent reporter, as well as an attP site, which acts as a landing platform for reintegration vectors. These vectors allow the insertion of a variety of transcription reporters or cDNAs to express tagged or mutant isoforms at endogenous levels. In addition, they pave the way for difficult experiments such as tissue-specific allele switching and functional analysis in post-mitotic or polyploid cells. Therefore, our method retains the advantages of homologous recombination while capitalising on the mutagenic power of CRISPR.